Kirsten rat sarcoma protein and hypoxia-inducible factor 1 alpha expression in colorectal cancer and its association with tumor clinicopathological features
Egyptian Journal of Pathology · 2026-01 · 46 (1) · 85-93
DOI: 10.4103/egjp.egjp_2_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Egyptian Journal of Pathology, online erschienen am 21.07.2026. Verfasst von Mohamed H. Elmahdi und 2 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) represents one of the most common cancers worldwide. It is ranked as the fourth most common cancer, accounting for nearly 10% of all cancers. Some tumor markers may help identify the prognosis of. One of those markers is the Kirsten rat sarcoma protein (KRAS). KRAS is one of the proteins important for the transduction cascade of the epidermal growth factor (EGF) and hypoxia-inducible factor 1 alpha (HIF-1a), which are essential mediators of cellular response to hypoxia, regulate gene expression for tumor angiogenesis, glucose metabolism, and resistance to oxidative stress.
Aim
To study the expression of KRAS and HIF-1a and its relationship with other clinical and histopathological prognostic factors in patients with CRC. Patients and methods This is a retrospective immunohistochemical study on 55 resection specimens from 55 CRC cases. The pathology specimens were collected from July 2019 to February 2020. Tumor tissues were prepared as formalin-fixed, paraffin-embedded specimens. The paraffin blocks were sectioned at a 5-micron thickness. Then the collected sections were stained with hematoxylin & eosin (H&E) for histopathological revision and immunohistochemical staining for KRAS and HIF-1a proteins.
Results
In our sample, only 54% of cases were positive for KRAS expression, and 50.9% were positive for HIF-1a. KRAS and HIF-1a expression showed no statistically significant relationship with the different clinical and histopathological parameters, including age groups, sex, histological variant, and tumor stages.
Conclusion
Immunohistochemical staining with KRAS and HIF-1a could be a promising, cost-effective modality for screening of mutations of CRC with results comparable to molecular studies. However, the interpretation of our results is limited by the small sample size of our population.
Zitieren
APA
Elmahdi, M. H., Elhamid, A. S. A., & Bayoumi, H. A. (2026). Kirsten rat sarcoma protein and hypoxia-inducible factor 1 alpha expression in colorectal cancer and its association with tumor clinicopathological features. Egyptian Journal of Pathology, 46(1), 85-93. https://doi.org/10.4103/egjp.egjp_2_26
Vancouver
Elmahdi MH, Elhamid ASA, Bayoumi HA. Kirsten rat sarcoma protein and hypoxia-inducible factor 1 alpha expression in colorectal cancer and its association with tumor clinicopathological features. Egyptian Journal of Pathology. 2026;46(1):85-93. doi:10.4103/egjp.egjp_2_26
BibTeX
@article{Elmahdi2026,
author = {Elmahdi, Mohamed H. and Elhamid, Alaa S. Abd and Bayoumi, Heba A.I.},
title = {Kirsten rat sarcoma protein and hypoxia-inducible factor 1 alpha expression in colorectal cancer and its association with tumor clinicopathological features},
journal = {Egyptian Journal of Pathology},
year = {2026},
volume = {46},
number = {1},
pages = {85--93},
doi = {10.4103/egjp.egjp_2_26}
}
EUVIMED